|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 2885 | Drugs / Medical | 11/10/2003
A class action has been filed against German drug manufacturer Bayer AG and several New Jersey hospitals on behalf of New Jersey postal workers who allege that they have suffered serious side effects from taking the antibiotic ciprofloxacin (Cipro) in the aftermath of the anthrax attacks in 2001. The action alleges that Bayer failed to warn the postal workers of Cupro's potential side effects, thereby violating the New Jersey Consumer Fraud Act. The action seeks funding for a medical monitoring program and compensatory damages for those workers who have suffered side effects.
The action alleges that the postal workers have suffered joint and tendon injuries; neurologic, cardiologic, or central nervous system disorders; and gastrointestinal disorders because of the Cipro that they were given to combat any possible anthrax infection. Allegedly, those workers who have not actually had negative side effects now have an increased risk of developing similar conditions. Additionally, the action alleges that there are increased risks of Cipro side effects in individuals who engage in athletics and in people who take nonsteroidal anti-inflammatory drugs. The action alleges that Bayer heavily promoted Cipro as the only safe and effective drug for use against Anthrax, so that persons who were exposed to infection were ordered or advised to take Cipro even though doxycycline and penicillin had been approved for anthrax prevention and several other antibiotics had been shown effective against anthrax bacteria. The action also alleges that, due to a strong increase in demand for Cipro after the anthrax attacks, Bayer made a steep hike in the drug's price, so that the retail price reached $7 per pill. Allegedly, Bayer paid millions of dollars to keep generic manufacturers from making Cipro, even though there were concerns about a shortage of the drug. The action alleges that sales of the drug skyrocketed 1,000 percent after the anthrax attacks. The action alleges that a Centers for Disease Control study indicated that Cipro consumers suffered significantly greater adverse effects than those cited in package inserts. The hospitals that dispensed Cipro allegedly failed to give the workers any written information about the drug. The action also alleges that the hospitals were negligent in distributing Cipro because they did not use physicians to prescribe or distribute it, did not take patient histories or do examinations, did not warn of the various side effects, and did not provide written information about the drug. In naming "Bayer Corporation" as an additional defendant, the action apparently means Bayer Pharmaceuticals Corporation, the U.S. subsidiary of Bayer AG. In Pennsylvania, a similar action covers employees of the Brentwood Post Office in Washington, D.C., workers at the U.S. Capitol, employees of American Media Inc. in Florida, and postal workers in general. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest A class action lawsuit has been filed in US District Court against Arkansas based Beverly Enterprises, Inc. d/b/a Beverly Healthcare The case involves violations of contract law. No additional information about the substance of the allegations is available at this time. Classactionamerica.com will monitor this case and provide additional details as soon as they become available. Several class actions have been filed against pharmaceutical development company POZEN, Inc., (Nasdaq:POZN) and certain of its officers and directors by stockholders who purchased the company's common stock between July 31, 2003, and May 28, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. Studies have now shown that light cigarette smokers compensate in various ways to make up for reduced levels of nicotine that they get. Two class actions have been filed against R.J. Reynolds Tobacco Company and Philip Morris USA, Inc., respectively, on behalf of all current or former smokers of Marlboro Lights, Camel Lights, Salem Lights, and Winston Lights in the state of Washington. The actions allege that the companies’ marketing strategies violate state consumer protection laws by actively concealing the fact that light cigarette smokers not only get as much or more tar as regular smokers, but may be smoking a more addictive product as well. Several class actions have been filed against pharmaceutical research and development company Entropin, Inc. (OTC BB:ETOP), and certain of its officers and directors on behalf of purchasers of stock and warrants in Entropin's March 15, 2000, public offering through which investors purchased units consisting of one share of common stock and one common stock purchase warrant. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market, thereby artificially inflating the price of the company's securities. A class action has been filed against Piedmont Medical Center Hospital in Rock Hill, South Carolina, on behalf of all patients who were treated from January 1, 1997 to the eventual date of any judgment in the action, alleging that the Tenet Healthcare-owned facility overcharged them in violation of its own price gap contract provisions that are designed to keep it from being the most expensive hospital in the vicinity. A class action has been filed against Axonyx Inc. (NasdaqSC:AXYX), and certain of its officers and directors by stockholders who purchased the company's common stock between June 26th, 2003 and February 4th, 2005. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The stockholders seek to recover compensatory damages for the loss of value of their stock. Axonyx Inc. is engaged in the business of acquiring and developing novel post-discovery central nervous system drug candidates, primarily in areas of memory and cognition. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
